Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

170 North Radnor Chester Road,Suite 250,Radnor, PA 19087-5279

Type of Company

Public

Employees (Worldwide)

28

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Contact Data
Trying to get in touch with decision makers at Marinus Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Vice President, Chief Financial Officer, Secretary & Treasurer

Chief Medical Officer

Vice President, Clinical Development & Pharmacovigilance

Vice President, Manufacturing

Vice President-Corporate & Business Development

Vice President, Clinical Development

Executive Director-Investor & Strategic Relations

Head of Regulatory Affairs

Vice President

Board of Directors

Partner at Domain Associates LLC

Chief Operating Officer & Director at Stat Medical Services, Inc.

Former Chief Medical Officer at Acorda Therapeutics, Inc.

President & Chief Executive Officer at Esperion Therapeutics, Inc.

Former President at Ortho-McNeil Pharmaceutical LLC

Former President & Chief Executive Officer at Adolor Corp.

Paths to Marinus Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Marinus Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Great Point Capital Management manages a research-driven, long/short equity hedge fund. The fund invests globally and focuses on small- to mid-cap US equities.

Details Hidden

VHCP Management focuses on investments in the stocks of US and European small-cap companies in the health technology sector.

Details Hidden

683 Capital Management focuses on investments in the stocks of US small-cap companies in the consumer services sector

Recent Transactions
Details Hidden

Marinus Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Marinus Pharmaceuticals, Inc. issued . USD Common Stock

Details Hidden

Marinus Pharmaceuticals, Inc. issued Common Stock

Transaction Advisors
Auditor

Advised onMarinus Pharmaceuticals, Inc. issued Common Stock

Escrow Agent

Advised onMarinus Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onMarinus Pharmaceuticals, Inc. issued . USD Common Stock

Managing Director, Equity Capital Markets Division

Advised onMarinus Pharmaceuticals, Inc. issued . USD Common Stock

Legal Advisor

Advised onMarinus Pharmaceuticals, Inc. issued . USD Common Stock

Legal Advisor

Advised onMarinus Pharmaceuticals, Inc. issued Common Stock

Clients

Rusnano OJSC operates as an investment company focusing on nanotechnology. Its activities include building nanotechnology infrastructure, which includes the nanotechnology centers of excellence, business incubators and early stage investment funds; It also provides scientific and educational programs. The company was founded on September 19, 2007 and is headquartered in Moscow, Russian Federation.

Key Stats and Financials As of 2018
Market Capitalization
$56.2M
Total Enterprise Value
$44.6M
Earnings Per Share
$-0.9
Revenue
$0
Net Profit
$-36.7M
EBITDA
$-37.1M
Total Debt
$0
Total Equity
$68.3M
TEVNet Income
-1.22x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

Flare Capital is a team of proven healthcare technology venture capital investors and senior operating executives known for their unparalleled strategic industry resources, insight and total commitment to the success of its entrepreneurs. Flare Capital raised one of the industry’s largest dedicated venture capital funds focused exclusively on early stage opportunities in healthcare technology innovation and is privileged to closely partner with founders and management.

Details Hidden

Executive Vice President & Chief Development Officer at Zogenix, Inc.

Details Hidden

President & Chief Executive Officer at Esperion Therapeutics, Inc.

Suppliers
Purdue Pharma LP Biotechnology | Stamford, CT

Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in various categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT.

Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Competitors
H. Lundbeck A/S Pharmaceuticals - Valby, CR

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

SAGE Therapeutics, Inc. Pharmaceuticals - CAMBRIDGE, MA

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

UCB S. A. Pharmaceuticals

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marinus Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marinus Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Marinus Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/marinus-pharmaceuticals-inc-111588
  • https://relationshipscience.com/organization/marinus-pharmaceuticals-inc-111588